CTLA4 blockade with tremelimumab diversifies the peripheral T-cell pool, representing a pharmacodynamic effect of how this class of antibodies modulates the human immune system.
No takes yet. Share an insight, caveat, or question.
Robert et al. (2014) studied this question.